BioMarin Pharmaceutical (BMRN) said Friday it will acquire Amicus Therapeutics (FOLD) for $4.8 billion in a deal that adds two rare disease drugs to its portfolio. In premarket trades on the stock market today, Amicus stock catapulted 29.8% to 14.13, just under the takeover price of $14.50 per share. The biotech stock is highly rated and has climbed roughly 94%…
Quick Read Bitcoin remains the stronger store of value, backed by its fixed 21 million supply, ETF demand, and growing...
Whenever you use your mobile phone or any other device hooked to the internet, you establish digital footprints. That footprint...
Apple famously rendered scores of startups and third-party tools obsolete with nearly every OS update since the mid-2000s. “Sherlocking” regularly...
Jupiter Wagons, a private company in the railway sector, reported a consolidated net profit of Rs 29 crore for the...
When most people think of Texas, what comes to mind is a gigantic state where alpha males rule the roost,...
Investors closely track the portfolios of leading market participants on Dalal Street. In this context, ETMarkets analysed the investment holdings...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
